Teva Pharma Industries Ltd ADR (TEVA)vsZoetis Inc (ZTS)
TEVA
Teva Pharma Industries Ltd ADR
$41.78
+1.99%
HEALTHCARE · Cap: $46.62B
ZTS
Zoetis Inc
$79.40
-3.30%
HEALTHCARE · Cap: $32.15B
Smart Verdict
WallStSmart Research — data-driven comparison
Teva Pharma Industries Ltd ADR generates 82% more annual revenue ($17.32B vs $9.53B). ZTS leads profitability with a 27.7% profit margin vs 4.1%. TEVA appears more attractively valued with a PEG of 1.02. ZTS earns a higher WallStSmart Score of 58/100 (C).
TEVA
Hold44
out of 100
Grade: D
ZTS
Buy58
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for TEVA.
Margin of Safety
+10.0%
Fair Value
$142.98
Current Price
$79.40
$63.58 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 72.2% YoY
Every $100 of equity generates 75 in profit
Strong operational efficiency at 40.7%
Safe zone — low bankruptcy risk
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Areas to Watch
4.1% margin — thin
Operating margin of 4.0%
Premium valuation, high expectations priced in
Revenue declined 0.8%
Trading at 10.4x book value
1.2% earnings growth
Expensive relative to growth rate
Revenue declined 0.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : TEVA
The strongest argument for TEVA centers on EPS Growth. PEG of 1.02 suggests the stock is reasonably priced for its growth.
Bull Case : ZTS
The strongest argument for ZTS centers on Return on Equity, Operating Margin, Altman Z-Score. Profitability is solid with margins at 27.7% and operating margin at 40.7%.
Bear Case : TEVA
The primary concerns for TEVA are Profit Margin, Operating Margin, P/E Ratio. A P/E of 66.6x leaves little room for execution misses. Debt-to-equity of 2.18 is elevated, increasing financial risk.
Bear Case : ZTS
The primary concerns for ZTS are Price/Book, EPS Growth, PEG Ratio. Debt-to-equity of 2.80 is elevated, increasing financial risk.
Key Dynamics to Monitor
TEVA profiles as a value stock while ZTS is a declining play — different risk/reward profiles.
TEVA carries more volatility with a beta of 0.82 — expect wider price swings.
ZTS is growing revenue faster at -0.2% — sustainability is the question.
ZTS generates stronger free cash flow (717M), providing more financial flexibility.
Bottom Line
ZTS scores higher overall (58/100 vs 44/100), backed by strong 27.7% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Teva Pharma Industries Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.
Zoetis Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Zoetis Inc. is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?